Join Drs. Kotton, Chemaly, and Papanicolaou as they illustrate how to use a new clinical decision support tool (CDST) for resistant or refractory cytomegalovirus (CMV) infection in hematopoietic cell transplant (HCT) patients. They will walk you through a challenging CMV resistant patient case and demonstrate how to enter clinical data into the novel CDST for optimal treatment decision making. Expert panel discussions provide an opportunity for you to learn how to apply the CDST in practice and incorporate a new therapy, maribavir, into the care of HCT patients with resistant or refractory CMV infection.
Upon completion of this activity, participants should be better able to:
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA
Professor, Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research Program
UT MD Anderson Cancer Center
Houston, TX
Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Medicine
Weill Cornell Medical College, Cornell University
New York, NY
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
